ALLO-501

N/A

Report date: 2024/04/17 20:05:34

Base Information

Drug NameALLO-501
Drug Alias Nameanti-CD19 monoclonal chimeric antigen receptor T-cell therapy抗CD19单克隆嵌合抗原受体T细胞（CAR-T）疗法Anti-CD19 CAR T cell therapyAnti-CD19 AlloCAR TALLO-501
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCellectis Sa
China Registration ClassN/A

Develop Information

Active CompaniesLaboratoires ServierAllogene Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A